Corcept Therapeutics (CORT) Operating Leases (2019 - 2026)
Corcept Therapeutics (CORT) posted Operating Leases of $9.4 million for Q2 2026, down 2.24% sequentially from $9.6 million in Q1 2026, and up 42.63% YoY from $6.6 million in Q2 2025.
Corcept Therapeutics (CORT) Operating Leases (2019 - 2026) Analysis & Trends
Corcept Therapeutics has reported Operating Leases for 7 years, with the latest figure at $9.4 million in Q2 2026.
- Quarterly Operating Leases rose 42.63% year-over-year to $9.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $9.4 million (up 42.63% YoY) and the FY2025 annual result came in at $5.0 million, down 17.75% from the prior year.
- Operating Leases eased to $9.4 million in Q2 2026 per CORT's latest filing, from $9.6 million in the prior quarter.
- Over five years, Operating Leases peaked at $9.6 million in Q1 2026 and troughed at $76000.0 in Q1 2024.
- A 5-year average of $4.2 million and a median of $5.0 million in 2025 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2023 and 2025: Operating Leases tumbled 86.88% in 2023, then soared 8893.42% in 2025.
- Over 5 years, Operating Leases stood at $1.1 million in 2022, then tumbled by 80.31% to $225000.0 in 2023, then jumped by 2614.22% to $6.1 million in 2024, then retreated by 17.75% to $5.0 million in 2025, then surged by 87.56% to $9.4 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $9.4 million, $9.6 million, and $5.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.42 Mn |
| Mar 31, 2026 | 9.64 Mn |
| Dec 31, 2025 | 5.02 Mn |
| Sep 30, 2025 | 6.36 Mn |
| Jun 30, 2025 | 6.61 Mn |
| Mar 31, 2025 | 6.84 Mn |
| Dec 31, 2024 | 6.11 Mn |
| Sep 30, 2024 | 6.79 Mn |
| Jun 30, 2024 | 5.67 Mn |
| Mar 31, 2024 | 76,000.00 |
| Sep 30, 2023 | 225,000.00 |
| Jun 30, 2023 | 297,000.00 |
| Mar 31, 2023 | 575,000.00 |
| Dec 31, 2022 | 1.14 Mn |
| Sep 30, 2022 | 1.71 Mn |
| Jun 30, 2022 | 2.26 Mn |
| Mar 31, 2022 | 2.80 Mn |
| Dec 31, 2020 | 501,000.00 |
| Sep 30, 2020 | 3.03 Mn |
| Jun 30, 2020 | 800,000.00 |